135 related articles for article (PubMed ID: 15289740)
1. Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.
Hausmaninger H; Morack G; Heinrich B; Wallwiener D; Höffken K; Buksmaui S; Krejcy K; Miller MA; Possinger K
Am J Clin Oncol; 2004 Aug; 27(4):429-35. PubMed ID: 15289740
[TBL] [Abstract][Full Text] [Related]
2. Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Palmeri S; Vaglica M; Spada S; Filippelli G; Farris A; Palmeri L; Massidda B; Misino A; Ferraù F; Comella G; Leonardi V; Condemi G; Mangiameli A; De Cataldis G; Macaluso MC; Cajozzo M; Iannitto E; Danova M
Oncology; 2005; 68(4-6):438-45. PubMed ID: 16020974
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and toxicity of gemcitabine combined vinorelbine on metastatic breast cancer: a report of 34 cases].
Zhou NN; Teng XY; Jiang WQ; Liu DG
Ai Zheng; 2007 Dec; 26(12):1373-6. PubMed ID: 18076805
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study.
Lüftner D; Flath B; Akrivakis C; Mergenthaler HG; Ohnmacht U; Arning M; Possinger K
Invest New Drugs; 1998; 16(2):141-6. PubMed ID: 9848577
[TBL] [Abstract][Full Text] [Related]
5. Single-agent gemcitabine is active in previously treated metastatic breast cancer.
Spielmann M; Llombart-Cussac A; Kalla S; Espié M; Namer M; Ferrero JM; Diéras V; Fumoleau P; Cuvier C; Perrocheau G; Ponzio A; Kayitalire L; Pouillart P
Oncology; 2001; 60(4):303-7. PubMed ID: 11408796
[TBL] [Abstract][Full Text] [Related]
6. Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: results of a multicenter phase II study.
Riccardi A; Brugnatelli S; Danova M; Giordano M; Pugliese P; Luchena G; Grasso D; Trotti G; Bertè R; Pansini G; Tinelli C
Tumori; 2006; 92(1):6-12. PubMed ID: 16683377
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Possinger K; Kaufmann M; Coleman R; Stuart NS; Helsing M; Ohnmacht U; Arning M
Anticancer Drugs; 1999 Feb; 10(2):155-62. PubMed ID: 10211545
[TBL] [Abstract][Full Text] [Related]
8. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
Schmid P; Krocker J; Schulz CO; Michniewicz K; Dieing A; Eggemann H; Heilmann V; Blohmer JU; Sezer O; Elling D; Possinger K
Anticancer Drugs; 2005 Jan; 16(1):21-9. PubMed ID: 15613900
[TBL] [Abstract][Full Text] [Related]
9. tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
Wardley AM; Hiller L; Howard HC; Dunn JA; Bowman A; Coleman RE; Fernando IN; Ritchie DM; Earl HM; Poole CJ;
Br J Cancer; 2008 Aug; 99(4):597-603. PubMed ID: 18665163
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
O'Shaughnessy JA; Pluenneke R; Sternberg J; Khandelwal P; Ilegbodu D; Asmar L
Clin Breast Cancer; 2006 Feb; 6(6):505-10. PubMed ID: 16595033
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
Yardley DA; Peacock NW; Dickson NR; White MB; Vázquez ER; Foust JT; Grapski R; Hendricks LK; Scott WL; Hainsworth JD
Clin Breast Cancer; 2010 Jun; 10(3):217-23. PubMed ID: 20497920
[TBL] [Abstract][Full Text] [Related]
12. First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
Allouache D; Gawande SR; Tubiana-Hulin M; Tubiana-Mathieu N; Piperno-Neumann S; Mefti F; Bozec L; Genot JY
BMC Cancer; 2005 Nov; 5():151. PubMed ID: 16316459
[TBL] [Abstract][Full Text] [Related]
13. Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study.
Shao B; Song G; Li H; Dil L; Jiang H; Liang X; Yan Y; Zhang R; Ran R; Wang J; Liu X; You M
J BUON; 2018; 23(6):1583-1590. PubMed ID: 30610781
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Conte PF; Gennari A; Donati S; Salvadori B; Baldini E; Bengala C; Pazzagli I; Orlandini C; Danesi R; Fogli S; Del Tacca M
Breast Cancer Res Treat; 2001 Jul; 68(2):171-9. PubMed ID: 11688520
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine plus Epi-doxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage: a phase II.
Neri B; Doni L; Fulignati C; Gemelli MT; Turrini M; Di Cello V; Dominici A; Mottola A; Raugei A; Ponchietti R; Cini G
Anticancer Res; 2002; 22(5):2981-4. PubMed ID: 12530029
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.
Pippen J; Elias AD; Neubauer M; Stokoe C; Vaughn LG; Wang Y; Orlando M; Shonukan O; Muscato J; O'Shaughnessy JA; Gralow J
Clin Breast Cancer; 2010 Apr; 10(2):148-53. PubMed ID: 20299319
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE
J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Hamm JT; Wilson JW; Rastogi P; Lembersky BC; Tseng GC; Song YK; Kim W; Robidoux A; Raymond JM; Kardinal CG; Shalaby IA; Ansari R; Paik S; Geyer CE; Wolmark N;
Clin Breast Cancer; 2008 Jun; 8(3):257-63. PubMed ID: 18650156
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.
Campone M; Fumoleau P; Viens P; Diéras V; Pujade-Lauraine E; Serin D; Petit T; Espié M; Kayitalire L; Bozec L; Pouillart P
Breast; 2006 Oct; 15(5):601-9. PubMed ID: 17045160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
